This call will be webcast live and can be accessed at the company’s website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company’s website and a replay of the call will be available from May 7^th through May 21^st at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay conference call access code is 13760146. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=yalsKXji

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,500 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

#     #     #

For Information Contact:

Christopher Belfiore

Director of Investor Relations

Varex Imaging Corporation

801.973.1566 | investors@vareximaging.com

The post VAREX SCHEDULES SECOND QUARTER FISCAL YEAR 2026 EARNINGS RELEASE AND CONFERENCE CALL appeared first on Varex Imaging.

What is an X-ray tube and why is it important in medical imaging?

An X-ray tube serves as the heart of every X-ray imaging system, converting electrical energy into X-ray radiation for medical diagnosis. Without this component, doctors could not see inside the human body and identify fractures, infections, or other medical conditions.

Medical X-ray tubes function as the radiation source in diagnostic imaging equipment. They enable healthcare professionals to capture images of bones, organs, and soft tissues without invasive procedures. From routine static X-rays to complex applications in computed tomography scanners, these devices make modern medical diagnosis possible.

The importance extends beyond basic radiography. X-ray tubes power mammography systems for breast cancer screening, dental imaging for oral health assessment, and fluoroscopy for real-time, interventional medical procedures. Each application requires specific tube designs optimized for imaging needs and patient safety requirements.

How does an X-ray tube produce X-rays?

X-ray production occurs through a controlled process of electron acceleration and collision. The tube heats a filament cathode to release electrons, accelerates them across a vacuum using high voltage, and directs them toward a metal target where X-rays form upon impact.

The process begins when electrical current heats the cathode filament, typically made of tungsten. This heating causes thermionic emission, releasing free electrons into the vacuum chamber. The number of electrons released determines the X-ray beam intensity.

High voltage, usually between 40 and 150 kilovolts, accelerates these electrons toward the anode target at tremendous speeds. When the high-energy electrons strike the target material, they interact with the metal’s atoms. This interaction converts approximately 1% of the energy from all the electrons into X-rays, while the remaining 99% becomes heat.

Two types of X-rays form during this process: characteristic X-rays from electron interactions with electrons of the target’s inner atomic shells, and bremsstrahlung radiation from electron deceleration near atomic nuclei. The combination creates the X-ray spectrum used for medical imaging.

What are the main components inside an X-ray tube?

An X-ray tube contains four primary components: cathode assembly, rotating target assembly or anode, vacuum chamber, and protective housing. Each component plays a specific role in X-ray generation and safe operation.

The cathode assembly includes the filament and focusing cup. The tungsten filament produces electrons when heated, while the focusing cup shapes and directs the electron beam toward the target. Most modern tubes use dual filaments for different focal spot sizes.

The anode serves as the target for electron bombardment. Rotating anodes distribute heat across a larger surface area, allowing higher power operation than stationary anodes. The target material, typically tungsten or tungsten–rhenium alloy, provides optimal X-ray production characteristics owing to its high-density melting temperature.

The vacuum chamber eliminates air molecules that would interfere with electron travel. The chamber, made of glass or metal, maintains the vacuum while allowing X-rays to exit through designated windows. The protective housing shields operators from radiation and provides electrical insulation.

Additional components include the rotor and stator assembly for anode rotation, high-voltage connections, and cooling systems. These elements work together to ensure reliable X-ray production and safe operation.

Why do X-ray tubes need to be replaced and how long do they last?

X-ray tubes require replacement due to gradual wear from heat stress, target and filament material erosion, and vacuum degradation. Most diagnostic X-ray tubes last 100,000 to 200,000 exposures, or 3–7 years, depending on usage patterns and maintenance quality.

Heat damage represents the primary cause of tube failure. Each X-ray exposure generates significant heat at the anode target, causing thermal stress and eventual cracking. Heavy usage, inadequate cooling, or excessive technique factors accelerate this wear process. Another primary contributor to X-ray tube failure can be the evaporation of the tungsten filament.

Vacuum loss occurs when the tube envelope develops microscopic leaks or when getter materials become saturated. Air molecules entering the vacuum interfere with electron flow, causing arcing and unstable X-ray output. Filament degradation also reduces electron emission over time.

Signs indicating tube replacement include increased exposure times, reduced X-ray output, image quality deterioration, unusual noises during operation, or frequent error messages. Regular maintenance and proper technique selection help maximize tube lifespan.

How Varex Imaging helps with X-ray tube technology

We provide advanced X-ray tube solutions that help OEM manufacturers develop superior imaging systems. Our tubes deliver reliable performance, extended lifespan, and innovative features that enable manufacturers to differentiate their products in competitive markets.

Our comprehensive X-ray tube portfolio includes:

• Rotating anode tubes for high-power diagnostic applications
• Stationary anode tubes for lower-power imaging needs
• Specialized mammography tubes for breast imaging systems
• CT tubes designed for computed tomography scanners
• Custom tube solutions for unique OEM requirements

We support OEM partners with engineering expertise, technical consultation, and rapid prototyping capabilities. Our global manufacturing facilities ensure consistent supply chain reliability, while our quality systems meet international medical device standards.

Partner with us to access innovative X-ray tube technology that helps you deliver superior imaging systems to healthcare providers worldwide. Contact our team to discuss your specific tube requirements and learn how we can support your next-generation imaging system development.

The post How does an X-ray tube work? appeared first on Varex Imaging.

What is an X-ray tube?

An X-ray tube serves as the radiation source for X-ray imaging systems, converting electrical energy into X-ray radiation that can pass through tissue with different tissues absorbing varying amounts of radiation to create the contrast visible on medical images. These diagnostic images enable doctors to visualize bone fractures, detect pneumonia, and perform medical procedures that support patient diagnosis.

Medical X-ray tubes operate at high voltages, typically between 40,000 and 150,000 volts, which allows them to produce X-rays with sufficient energy to penetrate human tissue.

What are the two main parts inside every X-ray tube?

Every X-ray tube contains two primary components: the cathode (negative electrode) that produces electrons, and the anode (positive electrode) that creates X-rays when those electrons strike it. These two parts work together inside a vacuum-sealed glass or metal housing to generate the X-ray radiation needed for medical imaging.

The cathode acts as the electron source, heating up to release a stream of electrons through a process called thermionic emission. Meanwhile, the anode serves as the target, made from materials like tungsten that can withstand electron bombardment while producing X-rays efficiently.

The cathode directs electrons across the vacuum space, and when these high-speed electrons impact the anode, they convert their kinetic energy into X-ray photons. This electron-to-photon conversion enables X-ray imaging.

How does the cathode create the electron stream?

The cathode creates electrons through thermionic emission, where an electrical current heats a thin tungsten filament to approximately 2,000°C, causing it to release electrons. A focusing cup surrounding the filament then shapes these electrons into a precise beam directed toward the anode.

The process occurs when electrical current flows through the tungsten wire, heating it until electrons gain sufficient energy to escape from the metal surface. Higher filament temperatures result in increased electron emission.

The focusing cup controls beam quality. This cup-shaped electrode surrounds the filament and uses its negative charge to concentrate the electron stream into a focused beam. Without proper focusing, the electrons would scatter in multiple directions, creating image degradation and energy loss. Most modern X-ray tubes have dual filaments of different sizes, allowing technicians to select between fine or broad electron beams depending on the imaging requirements.

What makes the anode so important in X-ray production?

The anode converts electron energy into X-rays when high-speed electrons strike its tungsten target surface. Most modern medical X-ray tubes use rotating anodes that spin at 3,000–10,000 RPM to distribute heat across a larger surface area, preventing damage from electron bombardment.

Tungsten functions as an effective anode material because it has a high atomic number (74) and a high melting point (3,422°C). When electrons impact tungsten atoms, they produce both X-rays and heat. Approximately 1% of the electron energy becomes useful X-rays, while the remaining 99% of the energy that converts to heat must be managed.

Rotating anodes address the heat management requirement. Instead of electrons hitting the same location repeatedly, the spinning motion distributes the impact across a circular track on the anode disc. This allows the tube to handle higher power levels and produce more X-rays without overheating. Some high-performance CT tubes can handle power levels exceeding 100 kilowatts, enabling rapid imaging sequences.

What protects everything inside the X-ray tube housing?

The protective housing surrounds the X-ray tube with lead shielding to contain radiation, cooling systems to manage heat, high-voltage insulation for safety, and vacuum seals to maintain the electron path. This housing protects both patients and operators while ensuring consistent tube performance.

Lead shielding forms the primary safety barrier, absorbing stray X-rays that don’t contribute to image formation. The housing typically contains several millimeters of lead-equivalent material, with a small window that allows the useful X-ray beam to exit while blocking radiation in all other directions.

Cooling systems prevent tube damage from heat buildup. Most housings contain oil that circulates around the tube, absorbing heat and transferring it to external heat exchangers. Some high-performance systems include active cooling with pumps and fans.

How do all these X-ray tube components work together?

The complete system works in sequence: electrical current heats the cathode filament, releasing electrons that accelerate toward the rotating anode, where they produce X-rays that pass through the housing window to create medical images. Each component must function properly for the X-ray tube to produce diagnostic-quality images.

The process begins when the X-ray technician selects exposure settings on the control panel. High voltage (typically 80–120 kV for diagnostic imaging) accelerates electrons from cathode to anode, while tube current (measured in milliamperes) determines how many electrons flow per second. The exposure time controls how long this process continues.

How Varex Imaging helps with X-ray tube technology

We provide comprehensive X-ray tube solutions that help medical equipment manufacturers create reliable, high-performance imaging systems. Our expertise spans the complete range of tube technologies, from standard diagnostic tubes to advanced CT systems that serve hospitals worldwide.

Our X-ray tube offerings include:

• High-performance rotating anode tubes for demanding clinical applications
• Specialized CT tubes designed for rapid, high-resolution imaging
• Advanced cooling systems that extend tube life and improve performance
• Custom tube designs tailored to specific imaging requirements
• Comprehensive support services to help manufacturers optimize their systems

Ready to learn more about how our X-ray tube technology can enhance your imaging systems? Visit our main site to explore our complete range of medical imaging components.

The post What are the main components of an X-ray tube? appeared first on Varex Imaging.

“We are excited to have successfully closed the new credit agreement and redeemed our senior secured notes, strengthening our balance sheet and improving our cost of capital,” said Sam Maheshwari, Chief Financial Officer of Varex Imaging Corporation. “We expect that the reduced debt and lower interest rate will improve financial flexibility, support improved free cash flow generation and enable continued investment in our core business while prioritizing long-term shareholder value,” added Maheshwari.

Borrowings under the Credit Agreement bear interest at a variable rate equal to the Secured Overnight Financing Rate (“SOFR”) plus an applicable margin, which is determined based on the company’s consolidated net leverage ratio. In connection with the financing, the company entered into an interest rate swap that effectively converts the variable SOFR component to a fixed SOFR of 3.65%. As of the closing of the Credit Agreement, the applicable margin is 2.50%. In connection with the refinancing, the company used approximately $42 million of cash, consisting of
an $18 million net reduction in outstanding debt, approximately $7 million in call premium paid to the Senior Secured Note holders, approximately $12 million of accrued interest on the redeemed notes, and approximately $5 million in transaction fees.

The refinancing is expected to reduce annualized cash interest expense by more than $7 million, reflecting lower interest rates and an $18 million reduction in outstanding debt.

Additional information concerning the Credit Facility is disclosed in Varex’s Form 8-K filed with the Securities and Exchange Commission today, March 16, 2026.

About Varex
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs  approximately 2,400 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Forward-Looking Statements
Statements made in this press release that are not historical facts, including statements accompanied by words such as “will,” “believe,” “strengthen,” “improve,” “support,” “enable,” “prioritize,” “expect,” “estimate,” “anticipate,” “increase,” “project,” “can,” “should,” “would,” “could,” “may,” “intend,” “potential,” and other words of similar expression, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s expectations, estimates, assumptions, and projections as of the date of this release and are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these statements. Factors that could cause actual results to differ materially include the need for greater borrowing under the Credit Facility than management’s current expectations, increases in the company’s consolidated net leverage ratio leading to higher interest rates, early termination of the company’s interest rate swap arrangement, and other factors that could cause interest rates to exceed current projections, as well as other risks set forth as risk factors in the company’s filings with the Securities and Exchange Commission, including its Quarterly and Annual Reports. The company cautions you not to place undue reliance on the forward-looking statements contained in this release. The company does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.

# # #
For Information Contact:
Christopher Belfiore
Director of Investor Relations
Varex Imaging Corporation
801.973.1566 | investors@vareximaging.com

The post VAREX ANNOUNCES SUCCESSFUL COMPLETION OF DEBT REFINANCING appeared first on Varex Imaging.

The post Varex Imaging at Sidoti Small Cap Virtual Conference appeared first on Varex Imaging.

The post Oppenheimer’s 36th Annual Healthcare, MedTech & Services Virtual Conference, Varex Imaging Presentation appeared first on Varex Imaging.

• Oppenheimer’s 36^th Annual Healthcare, MedTech & Services Virtual Conference: Tuesday, March 17, 2025 at 10:40am ET. Webcast link here.
• Sidoti Small Cap Virtual Conference: Wednesday, March 18, 2026 at 1:00pm ET. Webcast link here.

The webcast can be accessed at the above links or on Varex’s website at http://www.vareximaging.com/news.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,400 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

#     #     #

For Information Contact:

Christopher Belfiore

Director of Investor Relations

Varex Imaging Corporation

801.973.1566 | investors@vareximaging.com

The post VAREX MANAGEMENT TO PRESENT IN UPCOMING INVESTOR CONFERENCES appeared first on Varex Imaging.

The aggregate principal amount of the outstanding Notes is $368,000,000. The redemption price for the Notes will be equal to 101.969% of the principal amount of the Notes, together with accrued and unpaid interest on the Notes to, but not including the Redemption Date, for a total payment to holders of $1,052.72125 per $1,000 principal amount of the Notes.

The Company intends to fund the redemption of the Notes with proceeds from the funding of a new credit facility to be entered into between or among the Company and one or more lenders (the “New Financing”) and cash on hand. In accordance with the terms of the indenture governing the Notes, the obligation of the Company to redeem the Notes and pay the redemption price to the holders of the Notes on the Redemption Date is subject to consummation of the New Financing that will provide sufficient funds to pay the redemption price (the “Financing Condition”) and the Redemption Date may be delayed until the Financing Condition has been satisfied or waived by the Company. If the Financing Condition is not satisfied, the Company may elect to rescind the notice of conditional full redemption and terminate the redemption. If the Redemption Date is extended or the redemption is terminated, the Company will provide notice to holders of the Notes on the second business day immediately preceding the Redemption Date.

Assuming satisfaction or waiver by the Company of the Financing Condition, on and after the Redemption Date, the Notes will no longer be deemed outstanding, interest will cease to accrue thereon, and all rights of the holders of the Notes will cease, except for the right to receive the redemption price.

Payment of the redemption price for the Notes will be made in accordance with the applicable procedures of the Depository Trust Company.

Computershare Trust Company, N.A. is the trustee, collateral agent, paying agent and registrar of the Notes.

This press release is for information purposes only and shall not constitute a notice of redemption. The conditional redemption shall be made solely pursuant to the official notice of conditional full redemption required under the indenture governing the Notes, which notice shall be provided by the trustee on behalf of the Company. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the Notes or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Varex

Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices, and imaging software in their systems to detect, diagnose, protect, and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,400 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Forward-Looking Statements

Statements made in this press release that are not historical facts, including statements accompanied by words such as “will,” “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intend,” “potential,” and other words of similar expression, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s expectations, estimates, assumptions, and projections as of the date of this release and are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these statements. Factors that could cause actual results to differ materially include the inability of the Company to successfully complete the New Financing or to otherwise satisfy or waive the Financing Condition, as well as other risks set forth as risk factors in the Company’s filings with the Securities and Exchange Commission, including its Quarterly and Annual Reports. The Company cautions you not to place undue reliance on the forward-looking statements contained in this release. The Company does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.

#     #     #

For Information Contact:

Christopher Belfiore

Director of Investor Relations

Varex Imaging Corporation

801.973.1566 | investors@vareximaging.com

The post VAREX IMAGING CORPORATION TO REDEEM ITS 7.875% SENIOR SECURED NOTES DUE 2027 appeared first on Varex Imaging.

Q1FY26 Summary

• Revenues $210 million
• GAAP gross margin 33% | Non-GAAP gross margin* 34%
• GAAP operating margin 7% | Non-GAAP operating margin* 9%
• GAAP net income $0.05 per diluted share | Non-GAAP net income* $0.19 per diluted share
• Cash outflow from operations of $16 million

“We are pleased to report a solid start to fiscal 2026, with results toward the high-end of guidance. First quarter revenue of $210 million, increased 5% year-over-year. Growth in the quarter was driven by strength in our cargo systems business, which contributed to a 17% year-over-year increase in Industrial segment revenue” said Sunny Sanyal, Chief Executive Officer. Sanyal added, “Looking ahead, we expect demand for CT products to remain strong and we are encouraged by the sustained momentum in our cargo security systems business.”

Varex’s first quarter revenue of $210 million was up 5% year-over-year. Medical segment revenue was $145 million, while Industrial segment revenue was $65 million. Non-GAAP gross margin was 34% in the quarter compared to 35% in the first quarter of fiscal year 2025, and non-GAAP EPS increased to $0.19 in the quarter from $0.10 in the first quarter of fiscal year 2025.

Balance Sheet & Cash Flow

Cash outflow from operations was $16 million in the first quarter of fiscal year 2026. Cash, cash equivalents, and marketable securities was $126 million as of the end of the first quarter of 2026 compared to $155 million at the end of fiscal year 2025. The primary driver of the lower cash was an increase in working capital, primarily driven by inventory.

Outlook

Guidance for the second quarter of fiscal year 2026 is as follows:

• Revenues are expected to be between $210 million and $225 million
• Non-GAAP net earnings per diluted share is expected to be between $0.15 and $0.25

Guidance for the company’s net earnings per diluted share is provided on a non-GAAP basis only. This non-GAAP financial measure is forward-looking, and the company is unable to provide a meaningful or accurate reconciliation to a GAAP forecast of net earnings per diluted share without unreasonable effort due to certain of these reconciling items being uncertain, out of its control, and the amount and timing of these items being unable to be reasonably predicted. The actual amounts of such reconciling items could have a significant impact on the company’s GAAP net income (loss) per diluted share.

Non-GAAP Financial Measures

The company updated its non-GAAP policy related to equity-method investments beginning with the first quarter of fiscal year 2026. Please refer to “Reconciliation of 2025 Non-GAAP Financial Information As Previously Reported to 2025 Non-GAAP Financial Results as per Updated Policy – Excluding gains and losses from equity-method investments (Unaudited)” below.

Conference Call Information

Varex will conduct its earnings conference call for the first quarter of fiscal year 2026 today at 3:00 p.m. Mountain Time. The conference call, including a supplemental slide presentation, will be webcast live and can be accessed at Varex’s website at www.vareximaging.com/investor-relations. Access will also be available by dialing 877-524-8416 from anywhere in the U.S. or by dialing 412-902-1028 from non-U.S. locations. The webcast and supplemental slide presentation will be archived on Varex’s website at www.vareximaging.com/financial-reports. A replay of the call will be available from today through February 24^th at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay access code is 13758188. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=seewOOWX

About Varex

Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices, and imaging software in their systems to detect, diagnose, protect, and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,400 people located in North America, Europe, and Asia. For more information visit www.vareximaging.com.

Forward Looking Statements

This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning unaudited financial results; revenue and earnings guidance; industry or business outlook; product demand environment; expected future financial results or performance; and any statements using the terms “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intend,” and “potential,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company’s actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations. While forward-looking statements are based on assumptions and analyses made by management of Varex that it believes to be reasonable under the circumstances, actual results and developments will depend on a number of risks and uncertainties which could cause actual results, performance, and financial condition to differ materially from such expectations. Such risks and uncertainties include: changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto; reduction in or loss of business of one or more of the company’s limited original equipment manufacturing customers; global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, tariffs, trade wars, and other risks associated with international manufacturing, operations and sales; loss of business to, and an inability to effectively compete with, competitors; pricing pressures and other factors that could result in market erosion or loss of customers; failure to meet customers’ needs and demands; supply chain disruptions resulting in delayed product delivery, and increased costs as a result of reliance on a limited number of suppliers for certain key components; disruption of critical information systems or material breaches in the security of such systems; inability to maintain or defend intellectual property rights, and cost associated with protecting the company’s intellectual property and defending such rights and defending against infringement claims; non-compliance with regulations applicable to marketing, manufacturing, labeling, and distributing the company’s products and delays in obtaining regulatory clearances or approvals; limitations imposed by operating and financial restrictions of the company’s debt financing agreements; the financial results of the company’s equity method investments and joint ventures, and the other risks listed from time to time in the company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause the company’s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

Varex has not filed its Form 10-Q for the first quarter of fiscal year 2026. All financial results described here should be considered preliminary and are subject to change to reflect any necessary adjustments or changes in accounting estimates that are identified prior to the time Varex files its Form 10-Q.

#     #     #

For Information Contact:

Christopher Belfiore

Director of Investor Relations

Varex Imaging Corporation

801.973.1566 | christopher.belfiore@vareximaging.com

The post VAREX ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER FISCAL YEAR 2026 appeared first on Varex Imaging.

This call will be webcast live and can be accessed at the company’s website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company’s website and a replay of the call will be available from February 10th through February 24th at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay conference call access code is 13758188. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=seewOOWX

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,400 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

#     #     #

For Information Contact:

Christopher Belfiore

Director of Investor Relations

Varex Imaging Corporation

801.973.1566 | investors@vareximaging.com

The post VAREX SCHEDULES FIRST QUARTER FISCAL YEAR 2026 EARNINGS RELEASE AND CONFERENCE CALL appeared first on Varex Imaging.